Charles Weissmann's new office, squeezed into the corner of a London laboratory, seems in every sense too small for him. An imposing physical presence, his intellect also dominates the space with the kind of energy that can scarcely veil its impatience.
Weissmann, best known today for his contributions to the molecular biology of prion diseases such as scrapie and BSE, came to work at Imperial College School of Medicine at St Mary's in March, at the invitation of Britain's Medical Research Council. He had just retired from the University of Zurich in his native Switzerland, as director of the Institute of Molecular Biology which he founded 32 years ago. He is almost 68 but you could mistake him for a man 15 years younger. Perhaps this is because, by his own admission, he likes to challenge himself.
Not many people in their late sixties would give up a lifestyle that includes weekend skiing for the noise and frustration of London, but Weissmann is relishing the change. He had, in any case, vowed not to stay in his former department in a different role. "It is very disturbing for a successor to have his predecessor hanging around, trying to be a sort of éminence grise," he explains, grinning briefly at the thought. Originally, the MRC had wanted him to set up a new group in Cambridge. But he did not want to find himself in competition with John Collinge, head of the neurogenetics group at Imperial College, so he opted to join Collinge's group instead.
Weissmann's fascination with the spongiform encephalopathies began when he heard Stanley Prusiner talk on the subject in Perth, Australia, in 1982. Since then, his contributions have been critical. In particular, he and his colleagues cloned the gene that encodes the prion protein, PrP, in 1985 PrP, in and then, between 1990 PrP, in and 1992 attended a Portuguese-speaking school. Had the five years in Rio been a brake on his education? "On the contrary," he says. "I was challenged by having to continue my studies while also learning the language."
It hardly held him back. After earning degrees in medicine and biochemistry at Zurich, he went to the US in 1961. At New York University, he studied RNA phage replication, focusing on the RNA bacteriophage Qβ, which has only 4,300 nucleotides. (He remarks wryly that much of the molecular biology of Qβ remains unknown, and wonders aloud how some researchers can talk seriously about understanding 100,000 human genes.)
By 1967 he was back in Zurich, heading the institute, and in 1978 he and other leading molecular biologists founded the company Biogen. As he was already working in the institute on the cloning of mouse interferon, his group was commissioned by Biogen to clone human interferon cDNA. Success came unexpectedly over Christmas 1979; Weissmann, who had left the lab for a few days' skiing with the family, recounts how he heard the news in a call-box on top of a mountain, before rushing back to spend the rest of the holiday in the lab. Although his time with Biogen was enjoyable, 10 years were enough and from the late 1980s he was ready to concentrate again on basic research.
In fact, Weissmann not only enjoys basic research but also feels passionate about defending it. "One should cultivate basic research as one cultivates the arts," he says -and, as a fan of twentieth-century art and of the work of members of the London School, such as Francis Bacon, he is better placed than many colleagues to know what this means.
And his next project? Well, he gives himself about five years in London, then he will return to Switzerland. "I think that would be a good time to stop." But will he?
Phyllida Brown is a science writer based in London.
The amplification of oncogenes in human tumours is often mediated by little bits of extra-chromosomal DNA called double-minute chromosomes (DMs). If cancer cells lose these DMs, the cells revert to a normal growth pattern and become more susceptible to chemotherapy.
The larger image above shows a prometaphase spread of a cell from a colon cancer cell line in which DMs (containing c-myc oncogenes) have been labelled yellow and chromosomal DNA counterstained red. Importantly, the DMs are not distributed randomly; they cluster around the periphery of the prometaphase ring.
DMs can be removed from the nucleus by a molecular mechanism known as micronucleation, which is initiated by nuclear budding during S phase of the cell cycle. The inset image shows one of these nuclear buds (at bottom right) in which the DMs (yellow) have been selectively entrapped. The rate of micronucleation can be increased by the addition of replication inhibitors and, in normal human cells, is increased by inactivating the tumour suppressor p53. Such studies might help in the development of new strategies to encourage tumour cells to revert to normal growth by getting rid of their DMs. 
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